BPC-157 vs Uroguanylin
Head-to-head comparison of BPC-157 and Uroguanylin for research applications. Both peptides are studied for Gut Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Bpc 157 | Uroguanylin |
|---|---|---|
| Category | Healing & Recovery | GI / Metabolic |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. | Uroguanylin binds to GC-C receptors on the luminal surface of intestinal epithelial cells, stimulating intracellular cGMP production. |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical (for uroguanylin itself) / A for GC-C pathway |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Preclinical as a therapeutic. GC-C agonist drugs (linaclotide, plecanatide) are FDA-approved for IBS-C and chronic constipation. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Linaclotide and plecanatide (related GC-C agonists) have established safety profiles from Phase 3 trials and post-marketing surveillance; Primary side effect of GC-C activation is diarrhea (dose-dependent) |
| Molecular Weight | ~1419.5 g/mol | ~1667 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | N/A |
Overview
BPC-157 and Uroguanylin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
BPC-157 5mg
5mg
BPC-157 10mg
10mg
Uroguanylin — Mechanism & Evidence
Uroguanylin is a 16-amino-acid intestinal peptide hormone that activates guanylate cyclase C (GC-C) receptors on intestinal epithelial cells. It regulates fluid and electrolyte transport, intestinal barrier function, and has emerging roles in satiety signaling and colorectal cancer prevention. Uroguanylin is being studied as a more physiological approach to GC-C activation.
Key claims: Regulates intestinal fluid secretion; May act as a satiety hormone; Protects against colorectal cancer.
Shared Research Applications
Both peptides are studied for: Gut Health.
BPC-157 is also researched for: Injury Recovery.
Uroguanylin is also researched for: Metabolic Health.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Uroguanylin: Linaclotide and plecanatide (related GC-C agonists) have established safety profiles from Phase 3 trials and post-marketing surveillance Primary side effect of GC-C activation is diarrhea (dose-dependent) Uroguanylin itself has not been tested in human clinical trials as a standalone therapy
Shop Research Peptides
BPC-157 5mg
5mg
BPC-157 10mg
10mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
BPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides
FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.
Understanding Research Peptides vs. Pharmaceutical Peptides: BPC-157 News
This article explains the key differences between research peptides and pharmaceutical-grade peptides, with a focus on BPC-157. It covers regulatory status, purity standards, and intended use, providing clarity for researchers and industry professionals.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe